Altintas, AyseKarabudak, RanaBalci, Belgin P.Terzi, MuratSoysal, AysunSaip, SabahattinKurne, Asli Tuncer2024-09-182024-09-1820151074-7931https://doi.org/10.1097/NRL.0000000000000057https://hdl.handle.net/20.500.12483/11341Background: Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. Objective: To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. Methods: A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Results: Mean age was 38.43 +/- 12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29 +/- 12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Conclusion: Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or late-onset NMO, and no correlation between disability and NMO IgG status.eninfo:eu-repo/semantics/closedAccessneuromyelitis opticaneuromyelitis optica spectrum disorderaquaporin-4 antibodylate onsetprognosisclinical findingsArticle204616610.1097/NRL.0000000000000057264688702-s2.0-84945182146Q3WOS:000369951300002Q4